/IVACC.ST
IVACC.ST Stock - Intervacc AB (publ)
Healthcare|BiotechnologySTO
$0.92+1.99%
+$0.02 (+1.99%) • Dec 23
62
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.34
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.01
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for IVACC.ST
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.91 – $0.93
TARGET (TP)$1.06
STOP LOSS$0.85
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.63
52W High$1.35
52W Low$0.75
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $11.79M | $8.02M | $9.68M | $5.24M | $4.78M |
| Gross Profit | $-3,527,000 | $-13,806,000 | $3.37M | $6.25M | $4.64M |
| Gross Margin | -29.9% | -172.3% | 34.8% | 119.2% | 97.1% |
| Operating Income | $-77,277,000 | $-93,579,000 | $-64,413,000 | $-29,393,000 | $-25,676,000 |
| Net Income | $-75,515,000 | $-102,852,000 | $-64,158,000 | $-29,375,000 | $-25,601,000 |
| Net Margin | -640.7% | -1283.2% | -662.5% | -560.5% | -535.6% |
| EPS | $-0.86 | $-1.59 | $-1.11 | $-0.51 | $-0.47 |
Company Overview
Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in Nordic countries and the Baltic states. The company is based in Hägersten, Sweden.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
IVACC.STBeat Rate
38%
Last 8 quarters
Avg Surprise
-113.2%
EPS vs Estimate
Beats / Misses
3/5
Last 12 quarters
Latest EPS
$-0.04
Q4 2025
EPS Surprise History
Q1 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
-26.3%
$-0.24vs$-0.19
Q2 25
+57.9%
$-0.08vs$-0.19
Q3 25
+73.6%
$-0.05vs$-0.20
Q4 25
+72.8%
$-0.04vs$-0.15
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | May 12, 2026 | — | — | — | — |
Q1 2026 | Feb 16, 2026 | — | — | — | — |
Q4 2025 | Nov 19, 2025 | $-0.15 | $-0.04 | +72.8% | ✓ BEAT |
Q3 2025 | Aug 29, 2025 | $-0.20 | $-0.05 | +73.6% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.19 | $-0.08 | +57.9% | ✓ BEAT |
Q1 2025 | Feb 13, 2025 | $-0.19 | $-0.24 | -26.3% | ✗ MISS |
Q4 2024 | Nov 14, 2024 | — | $-0.25 | — | — |
Q3 2024 | Aug 29, 2024 | — | $-0.24 | — | — |
Q2 2024 | May 15, 2024 | — | $-0.23 | — | — |
Q1 2024 | Feb 16, 2024 | — | $-0.26 | — | — |
Q4 2023 | Nov 16, 2023 | — | $-0.63 | — | — |
Q3 2023 | Aug 31, 2023 | — | $-0.32 | — | — |
Q2 2023 | May 3, 2023 | — | $-0.30 | — | — |
Q1 2023 | Feb 17, 2023 | $-0.04 | $-0.40 | -964.1% | ✗ MISS |
Q4 2022 | Nov 10, 2022 | $-0.18 | $-0.25 | -40.7% | ✗ MISS |
Q3 2022 | Aug 31, 2022 | $-0.26 | $-0.27 | -4.4% | ✗ MISS |
Q2 2022 | May 20, 2022 | — | $-0.19 | — | — |
Q1 2022 | Feb 18, 2022 | $-0.09 | $-0.15 | -74.0% | ✗ MISS |
Q4 2021 | Nov 11, 2021 | — | $-0.14 | — | — |
Q3 2021 | Aug 31, 2021 | — | $-0.11 | — | — |
Latest News
Loading news...
Frequently Asked Questions about IVACC.ST
What is IVACC.ST's current stock price?
Intervacc AB (publ) (IVACC.ST) is currently trading at $0.92 per share. The stock has moved +1.99% today.
What is the analyst price target for IVACC.ST?
No analyst price targets are currently available for this stock.
What sector is Intervacc AB (publ) in?
Intervacc AB (publ) operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the STO exchange.
What is IVACC.ST's market cap?
Intervacc AB (publ) has a market capitalization of $0.31 billion, making it a small-cap company.
Does IVACC.ST pay dividends?
No, Intervacc AB (publ) does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorACARIX.ST
Acarix AB (publ)
$0.28
Mkt Cap: $0.3B
ACE.ST
Ascelia Pharma AB (publ)
$3.17
Mkt Cap: $0.4B
ELIC.ST
Elicera Therapeutics AB (publ)
$5.59
Mkt Cap: $0.3B
IMMU.ST
Mendus AB (publ)
$5.30
Mkt Cap: $0.3B
IRLAB-A.ST
IRLAB Therapeutics AB (publ)
$1.97
Mkt Cap: $0.2B
ISOFOL.ST
Isofol Medical AB (publ)
$0.72
Mkt Cap: $0.2B
KDEV.ST
Karolinska Development AB (publ)
$0.43
Mkt Cap: $0.1B
MAGLE.ST
Magle Chemoswed Holding AB (publ)
$17.20
Mkt Cap: $0.4B
MOB.ST
Moberg Pharma AB (publ)
$10.04
Mkt Cap: $0.5B
XINT.ST
Xintela AB (publ)
$0.27
Mkt Cap: $0.2B
Explore stocks similar to IVACC.ST for comparison